Floatz logo

Uproleselan

Acute Myeloid Leukemia

National Cancer Institute (NCI)Small moleculePhase 3Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
59/ 100

Competitive context

684 Active assets in the Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
Gemtuzumab
M.D. Anderson Cancer Center
Phase 4A
Cytosin-Arabinosid
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
AMSACRINE
University Hospital, Toulouse
Phase 4BBB
Posaconazole
AstraZeneca
Phase 4BBB
(+)-VINCRISTINE
Janssen Research & Development, LLC
Phase 3BBB

View all 50 →

Same molecule, other indications

Uproleselan is also rated in:

therapy related acute myeloid leukemia and myelodysplastic syndromeDormant
CCC
Indicative ·
52 / 100
View asset →
plasma cell myelomaDormant
CCC
Indicative ·
51 / 100
View asset →
therapy-related myeloid neoplasmDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →